MASH treatment – The Milli Chronicle

Thursday, October 9, 2025

Latest:

PepsiCo Sparkles with Strong Earnings and Fresh Leadership Amid Global Growth Momentum
Google Turns Cyber Threat into Triumph, Strengthens Global Digital Defenses Amid Oracle-Linked Hack
Elon Musk’s Visionary Tesla Deal Ignites Bold New Era for Innovation and AI Leadership
Novo Nordisk Makes Bold $5.2 Billion Move with Akero Buyout to Accelerate Liver Disease Breakthroughs
Wall Street’s Winning Streak: Investor Optimism Soars as U.S. Stock Options Reflect Renewed Market Confidence

Factual Version of a Story

Featured Health Lifestyle

NewsDesk Milli Chronicle October 9, 2025October 9, 2025 $5.2 billion deal, Akero Therapeutics, Akero Therapeutics stock, and future of liver disease treatment., biopharma deal 2025, biotech acquisition, biotech investment, biotech partnership, biotechnology news 2025, cardiometabolic health, clinical trial success, Denmark pharmaceutical industry, drug approval process, drug pipeline expansion, Efruxifermin, efruxifermin clinical trials, Eli Lilly competition, GLP-1 drug development, healthcare innovation, healthcare investment news, late-stage drug trials, liver disease drug, liver disease research, liver scarring reversal, MASH drug approval, MASH treatment, metabolic disease therapy, metabolic dysfunction-associated steatohepatitis, Mike Doustdar, Novo Nordisk, Novo Nordisk acquisition, Novo Nordisk CEO, Novo Nordisk global expansion, Novo Nordisk growth strategy, Novo Nordisk strategic acquisition, obesity and diabetes drugs, pharma R&D deal, pharmaceutical industry update, pharmaceutical innovation, pharmaceutical merger, pharmaceutical research and development, Wegovy manufacturer

Novo Nordisk Makes Bold $5.2 Billion Move with Akero Buyout to Accelerate Liver Disease Breakthroughs

In a landmark deal marking a new era under CEO Mike Doustdar, Novo Nordisk acquires Akero Therapeutics for up to